Fig. 2.

High-dose rhIL-2 significantly expands CD8 Foxp3+ T cells among skin-draining lymph nodes of tumor-free mice. a Cumulative analysis of CD8 Foxp3+ T cell frequency in lymphocytes isolated from spleen, PBMCs, and AB.LNs from control (untreated), drug vehicle (PBS + 0.1% (w/v) BSA), low-dose rhIL-2 (5,000 U) and high-dose rhIL-2 (50,000 U)-treated C57BL/6 mice. Data are expressed as mean percentage CD8 Foxp3+ T lymphocytes relative to total lymphocyte population ± SE. *P < 0.05 versus control (untreated) for site of lymphocyte origin. b Cumulative analysis of CD8 T lymphocytes (Foxp3−) frequency among lymphocytes isolated from spleen, PBMCs, and AB.LNs from control, drug vehicle, low-dose rhIL-2 (5,000 U) and high-dose rhIL-2 (50,000 U)-treated C57BL/6 mice. Data are expressed as mean percentage CD8 T cells relative to total lymphocyte population ± SEM. *P < 0.05 versus control (untreated) for site of lymphocyte origin